Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria.

CONTEXT Molecules that are released into biological fluids during matrix metabolism of articular cartilage, subchondral bone, and synovial tissue could serve as biochemical markers of the process of osteoarthritis (OA). Unfortunately, actual breakthroughs in the biochemical OA marker field are limited so far. OBJECTIVE By reviewing the status of commercially available biochemical OA markers according to the "Burden of disease, Investigative, Prognostic, Efficacy of intervention, and Diagnostic" ("BIPED") classification, future use of this "BIPED" classification is encouraged and more efficient biochemical OA marker research stimulated. DATA SOURCES Three electronic databases [PubMed, Scopus, EMBASE (1997-May 2009)] were searched for publications on blood and urinary biochemical markers in human primary knee and hip-OA. STUDY SELECTION Stepwise selection of original English publications describing human studies on blood or urinary biochemical markers in primary knee or hip-OA was performed. Selected articles were fully read to determine whether biochemical markers were investigated on performance within any of the "BIPED" categories. Eighty-four relevant publications were identified. DATA EXTRACTION Data from relevant publications were tabulated according to the "BIPED" classification. Individual analyses within a publication were summarized in general "BIPED" scores. DATA SYNTHESIS An uneven distribution of scores on biochemical marker performance and heterogeneity among the publications complicated direct comparison of individual biochemical markers. Comparison of categories of biochemical markers was therefore performed instead. In general, biochemical markers of cartilage degradation were investigated most extensively and performed well in comparison with other categories of biochemical markers. Biochemical markers of bone metabolism performed less adequately. Biochemical markers of synovial tissue metabolism were not investigated extensively, but performed quite well. CONCLUSIONS Specific biochemical markers and categories of biochemical markers as well as their nature, origin and metabolism, need further investigation. International standardization of future investigations should be pursued to obtain more high-quality, homogenous data on the full spectrum of biochemical OA markers.

[1]  Johanne Martel-Pelletier,et al.  Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes , 2005, Arthritis research & therapy.

[2]  D J Hunter,et al.  Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.

[3]  C. Yoon,et al.  Correlation of sonographic severity with biochemical markers of synovium and cartilage in knee osteoarthritis patients. , 2006, Clinical and experimental rheumatology.

[4]  O. Nemirovskiy,et al.  Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. , 2007, Analytical biochemistry.

[5]  P. Garnero,et al.  Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[6]  P. Delmas,et al.  Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. , 2001, Rheumatology.

[7]  J. Ross,et al.  A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts , 2009, Sexually Transmitted Infections.

[8]  J. Reginster,et al.  New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. , 2005, Osteoarthritis and cartilage.

[9]  I. Otterness,et al.  Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. , 2001, Journal of immunological methods.

[10]  J. Kumm,et al.  Associations between cartilage oligomeric matrix protein and several articular tissues in early knee joint osteoarthritis. , 2006, Rheumatology.

[11]  D. Eyre,et al.  The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. , 2009, Osteoarthritis and cartilage.

[12]  K. Brandt,et al.  Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing. , 2007, Arthritis and rheumatism.

[13]  P. Delmas,et al.  Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. , 2000, Arthritis and rheumatism.

[14]  V. Kraus,et al.  Variation in osteoarthritis biomarkers from activity not food consumption. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[15]  M. Dougados,et al.  Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. , 2002, Arthritis and rheumatism.

[16]  L. Sharma,et al.  The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. , 2007, Osteoarthritis and cartilage.

[17]  B. Månsson,et al.  Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[18]  J. Jordan,et al.  Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. , 2006, Arthritis and rheumatism.

[19]  S. Živanović,et al.  Human cartilage glycoprotein 39—biomarker of joint damage in knee osteoarthritis , 2009, International Orthopaedics.

[20]  B. Mazières,et al.  Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study , 2007, Annals of the rheumatic diseases.

[21]  Alice Maroudas,et al.  Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. , 2002, Arthritis and rheumatism.

[22]  S Zaim,et al.  Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study , 2006, Annals of the rheumatic diseases.

[23]  P. Garnero,et al.  PIIANP and HELIXII diurnal variation. , 2008, Osteoarthritis and cartilage.

[24]  J. Kirwan,et al.  A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis--association with disease progression. , 2007, Rheumatology.

[25]  E. Roos,et al.  Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis , 2006, BMC musculoskeletal disorders.

[26]  S. Wakitani,et al.  Serum keratan sulfate is a promising marker of early articular cartilage breakdown. , 2007, Rheumatology.

[27]  M. Nevitt,et al.  Biochemical markers of bone turnover and their association with bone marrow lesions , 2008, Arthritis research & therapy.

[28]  C. Peterfy,et al.  Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. , 2005, Arthritis and rheumatism.

[29]  B. Bresnihan,et al.  Synovial tissue inflammation in early and late osteoarthritis , 2005, Annals of the rheumatic diseases.

[30]  J. Wagner,et al.  Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.

[31]  Flavia Cicuttini,et al.  Association of cartilage defects with loss of knee cartilage in healthy, middle-age adults: a prospective study. , 2005, Arthritis and rheumatism.

[32]  C. Christiansen,et al.  Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. , 2008, Osteoarthritis and cartilage.

[33]  I. Petersson,et al.  Correlation between radiographically diagnosed osteophytes and magnetic resonance detected cartilage defects in the patellofemoral joint , 1998, Annals of the rheumatic diseases.

[34]  M. Dougados,et al.  Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. , 1997, Arthritis and rheumatism.

[35]  J. Singer,et al.  Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. , 2009, Arthritis and rheumatism.

[36]  D. Felson,et al.  Whither osteoarthritis biomarkers? , 2009, Osteoarthritis and cartilage.